Goodwin Procter and Wilson Sonsini Goodrich & Rosati represented MBX Biosciences, Inc. in the offering, and Davis Polk & Wardwell represented the underwriters. MBX Biosciences, Inc....
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati is representing LENZ Therapeutics in the transaction, Goodwin Procter is representing Graphite Bio and Latham & Watkins is representing the placements...
You must be a Standard 1 Year member to access this content.
Kyowa Kirin was represented by Goldman Sachs Japan Co., Ltd. as financial advisor and Morrison & Foerster LLP. as legal advisor. Orchard Therapeutics was represented by...
You must be a Standard 1 Year member to access this content.
Goodwin advised Astex on the agreement. Astex Pharmaceuticals (UK) announced its exclusive worldwide research collaboration and license agreement with MSD to identify small molecule candidates with...
You must be a Standard 1 Year member to access this content.
Bird & Bird advised Lonza, while Goodwin and NautaDutilh advised Synaffix. SynAffix B.V. announced the sale to Lonza Group AG. Under the terms of the sale and...
You must be a Standard 1 Year member to access this content.
Goodwin Procter acted as counsel to FibroGen, and Gibson Dunn acted as counsel to Morgan Stanley Tactical Value. FibroGen, Inc. (NASDAQ: FGEN) announced a non-dilutive term...
You must be a Standard 1 Year member to access this content.
Goodwin advised 30 Technology on the deal. 30 Technology announced the completed the sale of its antimicrobial nitric oxide platform in certain applications to Convatec Group Plc...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Synaffix on the deal. Synaffix announced a licensing agreement with Amgen to develop next generation of antibody-drug conjugates (ADCs) using Synaffix technology. Under the...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Ducentis BioTherapeutics on the deal. Ducentis BioTherapeutics announced its acquisition by Arcutis Biotherapeutics for up to $400 million. Ducentis BioTherapeutics, a portfolio company of...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Insempra on the deal. Insempra announced its strategic investment into Solena Materials Ltd (“Solena”) a synthetic biology company. Solena, a spin-out from Imperial College...
You must be a Standard 1 Year member to access this content.
Davis Polk & Wardwell, Mayer Brown, and Mishcon de Reya advised Gilead, while Goodwin Procter and Wilson Sonsini Goodrich & Rosati advised MiroBio on the deal....
You must be a Standard 1 Year member to access this content.
Goodwin advised ReViral on the deal. Clifford Chance advised Pfizer. ReViral announced its acquisition by Pfizer. Pfizer will acquire ReViral for a total consideration of up to...
You must be a Standard 1 Year member to access this content.
